Big results
Regulatory Information Disclaimer: Statements in this article regarding FDA actions, the 503B Bulks List, drug shortage status, and the federal regulatory framework for compounded GLP-1 medications reflect FDA published guidance current as of May 2026
West Virginia patients are left in limbo over changing insurance coverage of obesity medications West Virginia patients are left in limbo over changing insurance coverage of obesity medications CHARLESTON, W.Va
Engage in regular physical activity and maintain a balanced diet rich in whole foods
Leah Joseph, MD, FACP , youll receive a personalized treatment plan designed to optimize your health and wellness
For many patients on the weight-loss medications known as GLP-1s (glucagon-like peptide-1s), such as semaglutide, tirzepatide and liraglutide, the question of when or whether to stop is inevitable